


## Thalidomide-PEG2-NH2 hydrochloride

Cat. No.:	HY-133484B
CAS No.:	2891597-17-2
Molecular Formula:	C <sub>17</sub> H <sub>20</sub> ClN <sub>3</sub> O <sub>6</sub>
Molecular Weight:	397.81
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (314.22 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.5138 mL	12.5688 mL	25.1376 mL
		5 mM		0.5028 mL	2.5138 mL	5.0275 mL
		10 mM		0.2514 mL	1.2569 mL	2.5138 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.23 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	Thalidomide-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate ( <a href="#">E3 Ligase Ligand-Linker Conjugates</a> ) that incorporates the Thalidomide ( <a href="#">Thalidomide (HY-14658)</a> ) based cereblon ligand and a linker used in PROTAC technology <sup>[1]</sup> .
IC <sub>50</sub> & Target	Cereblon
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-996.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA